SCHEMBL3870144

SCHEMBL3870144

CSc1ccc(-c2cc(CCCC(=O)O)nn2-c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RXRA P19793 8/20 0.56
RXRB P28702 8/20 0.56
RXRG P48443 8/20 0.56
ILK Q13418 1/20 0.51
CYP2C9 P11712 1/20 0.51
ALOX5 P09917 2/20 0.49
PTGS2 P35354 4/20 0.48
EPHX2 P34913 3/20 0.48
AKR1C3 P42330 1/20 0.48
PTGS1 P23219 1/20 0.48
NR1H4 Q96RI1 1/20 0.44
KCNH2 Q12809 1/20 0.44
CHRNA7 P36544 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3865209 0.90 ILK (0.52) RXRARXRBRXRGILKCYP2C9
SCHEMBL3864045 0.85 EPHX2 (0.61) RXRARXRBRXRGCYP2C9ALOX5
SCHEMBL3870150 0.77 RXRA (0.50) RXRARXRBRXRGILKCYP2C9
SCHEMBL15560871 0.77 RXRA (0.62) RXRARXRBRXRGILKCYP2C9
SCHEMBL3870911 0.75 PTGS2 (0.54) CYP2C9PTGS2EPHX2PTGS1CHRNA7
SCHEMBL9519128 0.73 PTGS2 (0.57) RXRARXRBRXRGILKCYP2C9
SCHEMBL3865535 0.72 CHRNA7 (0.49) ILKCYP2C9ALOX5PTGS2EPHX2
SCHEMBL14728118 0.72 RXRA (0.80) RXRARXRBRXRGALOX5PTGS2
SCHEMBL15560693 0.72 ILK (0.74) RXRARXRBRXRGILKCYP2C9
SCHEMBL3869717 0.72 CHRNA7 (0.48) CYP2C9PTGS2EPHX2PTGS1CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2009-01-01 US disclosed
US-7442802-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-10-28 US disclosed
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-31 US disclosed
US-7087630-B2 Cyclooxygenase 2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-08 US disclosed
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 RXRA 4557/4885RXRB 4369/4885RXRG 4084/4885
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 RXRA 4557/4885RXRB 4369/4885RXRG 4084/4885
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE PTGS2, PTGIS, PTGES2 RXRA 4557/4885RXRB 4369/4885RXRG 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.